Nautilus Neurosciences, Inc., a New Jersey-based neurology-focused specialty pharmaceutical company, received an undisclosed investment from Galen Partners.
The new funds will support the growth of the company, and the upcoming launch of its first commercialized product, CAMBIA(TM), a novel, water-soluble, buffered diclofenac potassium powder for the acute treatment of migraine with or without aura.
In conjunction with the financing, Zubeen Shroff and David Azad, respectively managing director and principal at Galen Partners, have joined Nautilus’ board of directors.
The company was established in November 2009 with the acquisition of the migraine treatment CAMBIA and PRO-571, a product-development candidate for the potential treatment of acute pain.
The initial funding was provided by Tailwind Capital.
FinSMEs
13/04/2010